Cosmos Health Inc. (COSM) - Q1 2025 10-Q Summary
Business Context and Reporting Period
Company: Cosmos Health Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2025
Business Overview: An international healthcare group operating in the nutraceuticals, pharmaceuticals, and healthcare distribution sectors. Key subsidiaries include SkyPharm S.A. (Greece), Decahedron Ltd. (UK), and Cana Laboratories (Greece). The company focuses on proprietary brands ("Sky Premium Life," "Mediterranation"), generic pharmaceuticals, and AI-driven drug repurposing (Cloudscreen).
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $13,712,528 | $14,584,473 |
| Gross Profit | $2,049,799 | $1,333,626 |
| Gross Margin | 14.9% | 9.1% |
| Net Loss | $(818,097) | $(1,866,690) |
| Net Loss Per Share (Basic/Diluted) | $(0.03) | $(0.11) |
| Cash and Cash Equivalents | $742,881 | $315,105 (Dec 31, 2024) |
| Total Assets | $57,191,944 | $54,311,892 (Dec 31, 2024) |
| Total Liabilities | $31,240,232 | $29,778,963 (Dec 31, 2024) |
| Stockholders' Equity | $25,951,712 | $24,532,929 (Dec 31, 2024) |
| Working Capital | $1,259,012 | $(296,193) (Dec 31, 2024) |
Debt & Liquidity: Total debt obligations include Lines of Credit ($7.3M) and Notes Payable ($4.9M). The company reported positive working capital for the first time since the prior year-end, driven by inventory buildup and debt-to-equity conversions.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 6.0% year-over-year, primarily due to unfavorable foreign exchange movements (Euro depreciation) and a marginal decrease in wholesale sales.
- Improved Profitability: Net loss narrowed by 56.2% ($1.05M improvement). Gross profit increased 53.7% due to a strategic shift toward higher-margin nutraceutical products.
- Expense Reduction: Operating expenses decreased 9.1% ($286k), driven by a 17% reduction in salaries/wages and an 83.8% drop in sales and marketing expenses.
- Cash Flow: Net cash used in operating activities improved significantly to $(186k) from $(3.4M) in the prior year. Net cash provided by financing activities was $561k, supported by new debt facilities.
- Foreign Currency: A significant foreign currency translation gain of $1.03M contributed to a positive Total Comprehensive Income of $213k, contrasting with a loss of $2.5M in Q1 2024.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management explicitly states that conditions raise substantial doubt about the Company's ability to continue as a going concern for the next 12 months. This is due to an accumulated deficit of $114.8M and reliance on future capital raises.
- Strategic Plans: Management plans to access capital markets via an S-3 registration statement (eligible August 2025), expand the "Sky Premium Life" brand in the UAE (exclusive distribution agreement signed), and vertically integrate the supply chain.
- Nasdaq Compliance: The company received a notice of non-compliance with the $1.00 minimum bid price requirement but was granted a 180-day extension (until November 3, 2025) to regain compliance, potentially via a reverse stock split.
- Related Party Transactions: Significant transactions exist with Doc Pharma S.A. (related to the CEO's family), including large prepaid balances and loan receivables. The CEO's unpaid salaries were partially settled via stock issuance ($649k in Q1).
- Internal Controls: The company disclosed material weaknesses in internal controls, specifically regarding segregation of duties and IT General Controls.
Investor Verification Checklist
- Going Concern Viability: Verify the feasibility of the planned S-3 equity raise and the execution of the UAE distribution agreement to sustain operations.
- Related Party Exposure: Review the collectability of the $2.5M+ in receivables from related parties (Doc Pharma, Maria Kozari) and the terms of the $4.3M loan to Doc Pharma.
- Nasdaq Listing Status: Monitor the stock price to ensure compliance with the $1.00 minimum bid price by November 2025 to avoid delisting.
- Debt Covenants: Confirm continued compliance with financial covenants on lines of credit totaling $7.3M.
- Internal Control Remediation: Assess progress on fixing material weaknesses in financial reporting and IT controls by the stated deadline of December 31, 2025.